Zoe Price
Adelaide Medical School
Faculty of Health and Medical Sciences
I am currently undertaking a Doctor of Philosophy in the School of Medicine at the University of Adelaide. My project focusses on further understanding the role of hyaluronan, a extracellular matrix glycosaminoglycan, in ovarian cancer. In particular, determining the role of molecular weight of hyaluronan on ovarian cancer stem cell therapy resistance, proliferation, motility and invasion. Additionally, assessing hyaluronan molecular weight ranges as potential prognostic markers for ovarian cancer.
Research Interests:
- Hyaluronan
- Ovarian cancer
- Early detection and prognostic biomarkers
- Cancer Stem Cells
- Therapy Resistane
-
Appointments
Date Position Institution name 2018 - 2018 Research Assistant University of Adelaide -
Awards and Achievements
Date Type Title Institution Name Country Amount 2019 Scholarship Robert F Seamark Scholarship in Obstetrics and Gynaecology Robinson Research Institute Australia $10,000 -
Education
Date Institution name Country Title 2017 - 2017 University of Adelaide Australia Honours Degree of Bachelor of Health and Medical Sciences 2013 - 2015 University of Adelaide Australia Bachelor of Biomedical Science (Biochemistry and Immunology and Virology) -
Research Interests
-
Journals
Year Citation 2025 Noye, T. M., Mittal, P., Price, Z. K., Fewster, A., Williams, G., Pukala, T. L., . . . Ricciardelli, C. (2025). Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI. International Journal of Molecular Sciences, 26(12), 19 pages.
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.. Blood advances, bloodadvances.2024015238.
Europe PMC12025 Price, Z. K., Lokman, N. A., Morrison, J., Mhlanga, S. N., Sugiyama, M., Koya, Y., . . . Ricciardelli, C. (2025). Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.. J Cell Mol Med, 29(9), e70574.
2023 Varricchio, A., Khan, S., Price, Z. K., Davis, R. A., Ramesh, S. A., & Yool, A. J. (2023). Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. Cancers, 15(4), 1-20.
Scopus12 WoS4 Europe PMC82023 Price, Z. K., Lokman, N. A., Sugiyama, M., Koya, Y., Yoshihara, M., Oehler, M. K., . . . Ricciardelli, C. (2023). Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer. Cellular and Molecular Life Sciences, 80(11), 1-18.
Scopus3 Europe PMC32022 Leung, D., Price, Z. K., Lokman, N. A., Wang, W., Goonetilleke, L., Kadife, E., . . . Ahmed, N. (2022). Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism. Journal of Translational Medicine, 20(1), 556-1-556-23.
Scopus21 WoS7 Europe PMC212022 Price, Z. K., Lokman, N. A., Yoshihara, M., Kajiyama, H., Oehler, M. K., & Ricciardelli, C. (2022). Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. International Journal of Molecular Sciences, 24(1), 696.
Scopus17 WoS2 Europe PMC132019 Lokman, N. A., Price, Z. K., Hawkins, E. K., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2019). 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers, 11(8), 1-18.
Scopus41 WoS23 Europe PMC322019 Mittal, P., Price, Z. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Klingler-Hoffmann, M., & Hoffmann, P. (2019). Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for monitoring of drug response in primary cancer spheroids. Proteomics, 19(21 - 22), e1900146-1-e1900146-4.
Scopus19 WoS11 Europe PMC112018 Price, Z., Lokman, N., & Ricciardelli, C. (2018). Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers, 10(12), 482-1-482-21.
Scopus69 WoS49 Europe PMC46 -
Conference Papers
Year Citation 2024 Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. In BLOOD Vol. 144 (pp. 3214). ELSEVIER. 2024 Hung, K., Al-Kali, A., Toop, C., Patnaik, M. M., Price, Z., Kourelis, T., . . . Shah, M. (2024). <i>TP53</i>-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors. In BLOOD Vol. 144 (pp. 4594-4595). FL, Orlando: ELSEVIER.
DOI2024 Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. In BLOOD Vol. 144 (pp. 4596-4597). FL, Orlando: ELSEVIER.
DOI -
Conference Items
Connect With Me
External Profiles
